<DOC>
	<DOC>NCT02792192</DOC>
	<brief_summary>This Phase Ib/II study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, patient reported outcomes (PROs), and preliminary anti-tumor activity of atezolizumab administered by intravenous (IV) infusion alone or in combination with intravesical BCG in high-risk NMIBC participants.</brief_summary>
	<brief_title>Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Highrisk histologically confirmed nonmuscleinvasive termed transitional cell carcinoma (TCC) of the bladder with carcinoma insitu (CIS) Highrisk NMIBC defined by the following: BCGunresponsive NMIBC: Persistence of highgrade CIS at 6 months following an adequate course of BCG; or Stage/grade progression at 3 months after induction BCG; or Recurrence of highgrade CIS after achieving a diseasefree state (i.e., Complete Response [CR]) following induction of an adequate course of BCG that occurs &lt;6 months after the last exposure to BCG BCGrelapsing NMIBC: Recurrence of highgrade CIS after achieving a diseasefree state following induction of an adequate course of BCG that occurs &gt;/=6 months after the last exposure to BCG Very highrisk (VHR) BCGnaïve NMIBC: VHR NMIBC, defined as having at least 1 of the following: Multiple and/or large (&gt;3 cm) T1, (HG/G3) tumors T1, (HG/G3) tumor with concurrent CIS; T1, G3 with CIS in prostatic urethra; Micropapillary variant of nonmuscle invasive urothelial carcinoma For BCGunresponsive and BCGrelapsing NMIBC, participants must have received an adequate course of BCG Resection of all pTa/pT1 papillary disease No prior radiation to bladder; Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (&lt;/=) 2; Life expectancy more than or equal to (&gt;/=) 12 weeks Adequate hematologic and endorgan function Creatinine clearance &gt;/=30 mL/min (calculated using the CockcroftGault formula) For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (&lt;) 1% per year during the treatment period and for at least 90 days after the last dose of study drug Tumor tissue biopsy at study entry or availability of an archival specimen obtained within 2 months of study screening " Evidence of locally advanced, metastatic, muscleinvasive, and/or extravesical bladder cancer Any malignancy within 5 years prior to Cycle 1, Day 1 History of autoimmune disease, idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), druginduced pneumonitis, idiopathic pneumonitis, or active pneumonitis Signs or symptoms of infection within 2 weeks prior to the first dose of study treatment Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to the first dose of study treatment Treatment with any approved anticancer therapy within 3 weeks prior to the first dose of study treatment Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to the first dose of study treatment Pregnant or lactating women, or women intending to become pregnant during the study Prior allogeneic stem cell or solid organ transplantation Positive test for HIV Active hepatitis B or C and/or tuberculosis Severe infections within 4 weeks prior to the first dose of study treatment Significant cardiovascular disease Major surgical procedure other than for diagnosis within 4 weeks prior to the first dose of study treatment, or anticipation of need for a major surgical procedure during the course of the study History of prior significant toxicity or intolerance to BCG requiring discontinuation of treatment History of prior systemic BCG infection History of immunosuppression, or conditions associated with congenital or acquired immune deficiency Concurrent febrile illness, urinary tract infection, or gross hematuria Prior treatment with CD137 agonists or immune checkpoint blockade therapies Treatment with systemic immunostimulatory agents within 6 weeks or five halflives of the drug, whichever is shorter, prior to the first dose of study treatment Treatment with systemic immunosuppressive medications within 2 weeks prior to the first dose of study treatment, or anticipated requirement for systemic immunosuppressive medications during the trial"</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>